This proposal is in line with policies in place in countries such as the United Kingdom and Canada. The FDA’s draft recommendations are based on the agency’s careful review of available information, including data from other countries with similar HIV epidemiology that have instituted this approach, as well as ongoing surveillance of the U.S.A. blood supply.
To read the full FDA press release, please click here.